Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma

Piccardo, Arnoldo; Puntoni, Matteo; Lopci, Egesta; Conte, Massimo; Foppiani, Luca; Sorrentino, Stefania; Morana, Giovanni; Naseri, Mehrdad; Cistaro, Angelina; Villavecchia, Giampiero; Fanti, Stefano; Garaventa, Alberto

doi:10.1007/s00259-014-2691-0

Cited by 48 publications

(70 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a small study, sensitivity and specificity of approximately 90% were reported in stage III/IV neuroblastoma patients (67), with visualization of more disease sites and better assessment of response than with 123 I-MIBG (68). 18 F-DOPA lesion scores have also been evaluated, and a preliminary assessment showed a high correlation with the MIBG score (69). A higher prognostic correlation of metabolic burden detected with 18 F-DOPA was noted in this study.…”

Section: Other Net-targeting Tracerssupporting

confidence: 50%

Norepinephrine Transporter as a Target for Imaging and Therapy

Pandit‐Taskar

Modak

2017

J Nucl Med

View full text Add to dashboard Cite

The norepinephrine transporter (NET) is essential for norepinephrine uptake at the synaptic terminals and adrenal chromaffin cells. In neuroendocrine tumors, NET can be targeted for imaging as well as therapy. One of the most widely used theranostic agents targeting NET is metaiodobenzylguanidine (MIBG), a guanethidine analog of norepinephrine. 123 I/ 131 I-MIBG theranostics have been applied in the clinical evaluation and management of neuroendocrine tumors, especially in neuroblastoma, paraganglioma, and pheochromocytoma. 123 I-MIBG imaging is a mainstay in the evaluation of neuroblastoma, and 131 I-MIBG has been used for the treatment of relapsed high-risk neuroblastoma for several years, however, the outcome remains suboptimal. 131 I-MIBG has essentially been only palliative in paraganglioma/pheochromocytoma patients. Various techniques of improving therapeutic outcomes, such as dosimetric estimations, high-dose therapies, multiple fractionated administration and combination therapy with radiation sensitizers, chemotherapy, and other radionuclide therapies, are being evaluated. PET tracers targeting NET appear promising and may be more convenient options for the imaging and assessment after treatment. Here, we present an overview of NET as a target for theranostics; review its current role in some neuroendocrine tumors, such as neuroblastoma, paraganglioma/ pheochromocytoma, and carcinoids; and discuss approaches to improving targeting and theranostic outcomes.

show abstract

Section: Other Net-targeting Tracerssupporting

confidence: 50%

Norepinephrine Transporter as a Target for Imaging and Therapy

Pandit‐Taskar

Modak

2017

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…In addition, patients with a 18 F-DOPA WBMB [7.5 displayed a significantly higher risk of disease progression and death than those with 18 F-DOPAWBMB B7.5 [34]. At multivariate analysis, including all principals prognostic factors at the time of NB relapse, the authors report a significant association between 123 I-mIBG score and 18 F-DOPA WBMB with respect to progression free survival (PFS).…”

Section: Comparison With Conventional Radiological Imagingmentioning

confidence: 96%

“…In this context, only the paper by Piccardo and colleagues evaluated the prognostic role of 123 I-mIBG scintigraphy and 18 F-DOPA-PET/CT at the time of NB relapse [34]. Firstly, the authors introduced a new 18 F-DOPA-PET/CT score to assess the whole-body burden of NB.…”

Section: Comparison With Conventional Radiological Imagingmentioning

confidence: 99%

Potential role of 18F-DOPA PET in neuroblastoma

Piccardo

Lopci

2016

Clin Transl Imaging

Self Cite

View full text Add to dashboard Cite

18 F-3,4-Dihydroxyphenylalanine (DOPA) is the radio-labelled analogue of DOPA, a precursor of dopamine and catecholamines. It is a multivalent molecule that is widely used for functional imaging of various neural crest tumors, documenting a better diagnostic accuracy compared to 123 I-metaiodobenzylguanidine ( 123 I-mIBG) scintigraphy and other conventional imaging modalities. Neuroblastoma (NB) is an embryonic tumor deriving from the peripheral sympathetic nervous system, commonly included into the vast group of neural crest tumors. So, it maintains the ability to produce and release biologically active amines and in most cases is characterized by an increased metabolism of catecholamines. 123

show abstract

“…FDG PET has been shown to be of prognostic value [18]. 68 Ga-DOTATATE PET [19,20], 18 F-fluorodopa PET [21,22] and labeled monoclonal antibody scans [23] may also be of value. Nonetheless, despite this embarrassment of riches in the techniques available for imaging neuroblastoma, 123 I-mIBG remains the gold standard, and semi-quantitative skeletal scoring as described by Lewington et al [1] should become the new norm.…”

mentioning

confidence: 99%